Kalorama: New Drug Development Drives $2 Billion Future Market for CRISPR and Other Gene Editing Tech
ROCKVILLE, Md., Oct. 31, 2016 /PRNewswire/ -- The global market for gene editing technologies is a young market that is expanding rapidly as the technologies find a multitude of commercial applications in fields such as biopharmaceuticals, agriculture, and industrial products, according to a recent report from market research firm Kalorama Information. In its new report, Gene Editing Markets, the healthcare market research publisher finds that, despite its recent discovery, the CRISPR-based gene editing technology has expanded and accelerated the adoption and use of gene editing in various fields, and is expected to continue to drive the rapid growth of this market to nearly $2 billion by 2020.
Gene Editing Markets (CRISPR-based, Zinc Finger Nuclease [ZFN], TALEN, Other) can be found at Kalorama Information: http://www.kaloramainformation.com/Gene-Editing-CRISPR-10347331/?productid=10347331.
The increasing development of therapeutics and agricultural applications using gene editing technologies, as well as the growing public and private investments and funding in the gene editing area are among the driving forces in this market. The development of human therapeutics using gene editing technologies is an area of major interest that has recently received large public and private investments.
The initial applications of gene editing technologies have largely focused on the treatment of monogenic disorders, but other areas, such as immuno-oncology, have also witnessed recently a growing interest from the bio-pharmaceutical industry. Companies such as Bayer, Biogen IDEC, Juno Therapeutics, Novartis, Pfizer and Regeneron Pharmaceuticals are involved in the development of therapeutics using gene editing technologies through various investments and collaborations with smaller companies.
While Sangamo Biosciences and Cellectis are leaders in this field, having the most advanced drug candidates in the pipeline, several startup companies – including CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and PoseidaTherapeutics– have been recently established to use the newer CRISPR-based gene editing technologies for the engineering of human therapeutics. Most of these companies are in the US and Europe, but China has also advanced rapidly in this area, as two CRISPR-engineered drug candidates developed in China have already entered clinical trials in 2016 for the treatment of cancer.
In addition to the development of human therapeutics, gene editing technologies have commercial applications in numerous other fields, many of which are just beginning to be explored. Key players in the market for gene editing technologies include Millipore Sigma, ThermoFisher Scientific, Dharmacon, GeneCopoeia, GenScript, Horizon Discovery Group, OriGene, Transposagen, and ToolGen.
"The competition increased in the past two years, as a flurry of CRISPR/Cas9 commercial products were introduced to market", says analyst Adriana Rusu, author of this report. "While the ZFN and TALEN technologies still offer distinct advantages, a large part of this market is moving towards the CRISPR technology, which is more versatile, easy to use, and inexpensive compared to the other technologies. The activity in the CRISPR segment is expected to further intensify, despite the patent disputes and regulatory uncertainties surrounding these technologies."
Current genome editing technologies encompass several classes of programmable nucleases, including mononucleases, zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), and CRISPR(clustered regularly interspaced short palindromic repeats)-Cas9nuclease systems.
Kalorama Information's report, Gene Editing Markets examines in detail these technologies, as well as the global industry, its structure and major trends affecting it, and provides revenue forecasts by technology, product type, application area, and geographic regions. Profiles of various competitors in this industry are also included in this report. The report can be found at: http://www.kaloramainformation.com/Gene-Editing-CRISPR-10347331/?productid=10347331.
Please link any media or news references to our reports or data to http://www.kaloramainformation.com/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO
SOURCE Kalorama Information
Share this article